NICE (UK) terminated appraisal for Onivyde (pegylated liposomal irinotecan) in combination for untreated metastatic pancreatic cancer – Servier

NICE (UK) is unable to make a recommendation about the use in the NHS of pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer in adults.

This is because Servier has confirmed that it does not intend to make an evidence submission for the appraisal. Servier considers that there is unlikely to be enough evidence that the technology is a cost-effective use of NHS resources for this population.